JP2005525398A - ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 - Google Patents

ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 Download PDF

Info

Publication number
JP2005525398A
JP2005525398A JP2003584046A JP2003584046A JP2005525398A JP 2005525398 A JP2005525398 A JP 2005525398A JP 2003584046 A JP2003584046 A JP 2003584046A JP 2003584046 A JP2003584046 A JP 2003584046A JP 2005525398 A JP2005525398 A JP 2005525398A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
mmol
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003584046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525398A5 (enExample
Inventor
カーソン，ジヨン・アール
ジエツター，マイケル・シー
リー，ジヤング・エス
ヤングマン，マーク・エイ
Original Assignee
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド filed Critical オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Publication of JP2005525398A publication Critical patent/JP2005525398A/ja
Publication of JP2005525398A5 publication Critical patent/JP2005525398A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003584046A 2002-04-10 2003-03-31 ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 Withdrawn JP2005525398A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37135002P 2002-04-10 2002-04-10
PCT/US2003/009974 WO2003087090A2 (en) 2002-04-10 2003-03-31 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

Publications (2)

Publication Number Publication Date
JP2005525398A true JP2005525398A (ja) 2005-08-25
JP2005525398A5 JP2005525398A5 (enExample) 2006-05-25

Family

ID=29250669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003584046A Withdrawn JP2005525398A (ja) 2002-04-10 2003-03-31 ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体

Country Status (6)

Country Link
US (2) US6958349B2 (enExample)
EP (1) EP1495017A2 (enExample)
JP (1) JP2005525398A (enExample)
AU (1) AU2003226188A1 (enExample)
CA (1) CA2481855A1 (enExample)
WO (1) WO2003087090A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516132A (ja) * 2002-12-19 2006-06-22 エラン ファーマシューティカルズ，インコーポレイテッド 置換ｎ−フェニルスルホンアミドブラジキニン拮抗薬
JP2016514141A (ja) * 2013-03-14 2016-05-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
WO2008026018A1 (en) * 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
US7807629B1 (en) 2007-06-05 2010-10-05 Alcon Research, Ltd. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
US8173668B1 (en) 2007-06-05 2012-05-08 Alcon Research, Ltd. Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
EP2830643A1 (en) 2012-03-26 2015-02-04 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for prevention or treatment of ischemia related organ damage
BR112016030787B1 (pt) * 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
SMT202200154T1 (it) 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
HRP20260166T1 (hr) 2022-03-25 2026-03-27 Pharvaris Gmbh Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora
CN117342963B (zh) * 2023-09-28 2025-06-17 上海予君生物科技发展有限公司 一种1,4-二羰基化合物、及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
AU686115B2 (en) * 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19712960A1 (de) * 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
WO1999051235A1 (en) * 1998-04-03 1999-10-14 Alcon Laboratories, Inc. Non-peptide bradykinin receptor antagonists for use in controlling intraocular pressure and treating glaucoma
EP1123288A1 (en) * 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516132A (ja) * 2002-12-19 2006-06-22 エラン ファーマシューティカルズ，インコーポレイテッド 置換ｎ−フェニルスルホンアミドブラジキニン拮抗薬
JP2016514141A (ja) * 2013-03-14 2016-05-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法

Also Published As

Publication number Publication date
US20050159443A1 (en) 2005-07-21
US7358261B2 (en) 2008-04-15
WO2003087090A3 (en) 2003-12-11
US20040192720A1 (en) 2004-09-30
AU2003226188A1 (en) 2003-10-27
US6958349B2 (en) 2005-10-25
EP1495017A2 (en) 2005-01-12
AU2003226188A8 (en) 2003-10-27
WO2003087090A2 (en) 2003-10-23
CA2481855A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US6958349B2 (en) Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ES2225231T3 (es) Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
JP5235887B2 (ja) Ｒｈｏキナーゼ阻害剤
AU748091B2 (en) Indole derivatives as MCP-1 receptor antagonists
US6770639B2 (en) Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP4778954B2 (ja) オピオイド受容体調節薬としての新規な化合物
AU679049B2 (en) Antipsychotic benzimidazole derivatives
ES2258331T3 (es) Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos.
KR101804588B1 (ko) 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도
US20030119830A1 (en) Monocyte chemoattractant protein-1 inhibitor compounds
KR20040048995A (ko) 퀴놀린 화합물
JP2007517800A (ja) 糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての（３−オキソ−３，４−ジヒドロ−キノキサリン−２−イル−アミノ）−ベンズアミド誘導体および関連化合物
JPH08225570A (ja) 新規ピペリジン化合物、それらの製造法、およびそれらを含有する製剤組成物
AU4333299A (en) Quinazolinone inhibitors of cgmp phosphodiesterase
CN101616667A (zh) 可用作激酶抑制剂的杂环酰胺化合物
JP2014502266A (ja) 造血成長因子模倣体の使用
EP2070928A1 (en) 7-azaindol-3-ylacrylamides active as kinase inhibitors
JP2004506636A (ja) チロシンキナーゼのインヒビターとして有用な複素環化合物
KR20140124398A (ko) 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
JP2010507664A (ja) ベンズイミダゾール化合物
EP0978514B1 (en) Indazole derivatives as 5-HT1F agonists
FI80690B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4,5-dihydro-1h-imidazol-2-yl)-2,3-dihydro- indolderivat.
CA2426089A1 (en) Bombesin receptor antagonists
KR20020064375A (ko) Ｍｃｐ-1 수용체 길항제인 인돌 유도체
WO2004092136A1 (ja) 含窒素複素環化合物およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060331

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080427

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090219